about
Tumor angiogenesis: pericytes and maturation are not to be ignoredTrastuzumab-containing regimens for metastatic breast cancerFollow-up strategies for women treated for early breast cancerBrain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatmentTargeting Breast Cancer MetastasisThe network of pluripotency, epithelial-mesenchymal transition, and prognosis of breast cancerA hypoxic ticket to the bone metastatic nicheFuture directions for the early detection of recurrent breast cancerSWIFT MRI enhances detection of breast cancer metastasis to the lungImplications of Hypoxia in Breast Cancer Metastasis to BoneBreast cancer brain metastases: biology and new clinical perspectivesSystemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesHER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancerChemopreventive Activity of Ferulago angulate against Breast Tumor in Rats and the Apoptotic Effect of Polycerasoidin in MCF7 Cells: A Bioassay-Guided ApproachDifferential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel'Omic approaches to preventing or managing metastatic breast cancerImpact of molecular subtypes on metastatic breast cancer patients: a SEER population-based studyExpression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.Collective invasion in breast cancer requires a conserved basal epithelial program.A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer.Brain metastasis: clinical characteristics, pathological findings and molecular subtyping for therapeutic implications.Are metastases from metastases clinical relevant? Computer modelling of cancer spread in a case of hepatocellular carcinoma.Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up.Phase II open-label study of sunitinib in patients with advanced breast cancer.Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicinRunx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to mesenchymal transition.Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.Downregulation of delta-aminolevulinate dehydratase is associated with poor prognosis in patients with breast cancer.Computational analysis of mRNA expression profiles identifies the ITG family and PIK3R3 as crucial genes for regulating triple negative breast cancer cell migrationLong-term survivor characteristics in HER2-positive metastatic breast cancer from registHER.Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer.The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: a SEER based studyMeasures of outcome in metastatic breast cancer: insights from a real-world scenarioBreast cancer subtypes predict the preferential site of distant metastases: a SEER based studyImpact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.Imaging Surveillance After Primary Breast Cancer Treatment.Progress in the biological understanding and management of breast cancer-associated central nervous system metastases.miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancerDifferential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab
P2860
Q21296683-D151B0FB-930C-4B74-80EB-55D1D4DDE4BEQ24194019-AC4C6EAF-01E6-4831-B068-1A566A54FE12Q26471890-1A5702F6-68D8-44BB-A9AF-B06736E9AA6CQ26751008-78583909-6E89-4BF2-92CA-A48F145E4526Q26783925-5CA784BE-382A-4730-903A-FA8BF3F87CBCQ26785448-0DA28A97-F52B-4454-A1CF-A334D3485B1DQ26785895-15701709-AFF4-4367-96CB-B08386D2FB42Q27022040-7DF727E1-BEB8-457A-BB08-196BB84D8346Q27332404-D212196B-76D1-4A39-9BCF-DF8CC95F439DQ28077444-6315DB64-8249-43F2-BDFC-E40378B8F060Q28078998-E31A43A4-BCDA-45D5-99DF-E9AD0995C471Q28080469-2F260151-B72A-44FA-82C7-C634C72D503FQ28085413-C7EC1D14-C5FD-4C2A-9475-58FFF575891AQ28547418-95702132-CAA7-4189-AFE9-A4E15B8C0503Q28728830-F7736CEA-EDBC-4F58-8704-25087F399246Q28730572-D6076AC5-AF36-4C85-B6A3-C6B1AE782701Q29248323-6260C370-2D59-44DA-A430-320D5F3C6D29Q30491493-61CBDAEC-2615-4FCD-99A4-338C325FB246Q30573307-50692D8F-644A-49D7-A1DF-9C8E344328F1Q30587056-B834B5BD-E400-4FD7-A96D-79514E4CCE16Q31010216-9B4FB6F7-260A-4EB6-BA82-82B5E6BCBF84Q31060250-AB62DE8A-CBA8-4E9E-A946-38FAEE3DBDE9Q31154571-C2F73458-EF97-4048-9340-769E45B1E056Q33403848-0BE43F3F-C63C-4B0E-A6FA-983ACBF0EE3CQ33422353-3AE194AE-C29C-42D2-BB0A-8BE80755A48AQ33566597-82803612-CCA0-41C9-B166-13FEC18D321AQ33600072-4671799E-3FA6-4421-9ABF-AA688070C848Q33607424-69E3A641-3BF6-4F6F-9CC9-DA649276EE0AQ33657062-AC5B9B76-7137-41D3-BDEF-B5B0CF3FA748Q33682910-9435197F-C6E2-486C-8707-4FE991D72641Q33683120-C0E964C6-731A-4548-9B0C-FCE8C27F2A27Q33683344-1C5F054B-299F-4B42-94AB-D92C331B43F3Q33688668-1DA6734C-5B21-4C34-8F8B-D3C673834EC2Q33699649-C3529AB7-C761-41CC-83A3-D7A140E486CAQ33709532-81009076-C987-4EA3-9BC0-315196F7F62CQ33739253-BA14229E-6AC9-4353-8C5E-1D31A32B9151Q33763563-6B889EEF-8415-44B1-B3EF-9FD9E2DABF4AQ33777436-5E6C9AB2-6011-4C46-849C-93D000498794Q33815074-454DA69E-C106-4630-B341-3E1334F881E4Q33843810-E8267614-20D6-4E49-A140-B83CCA0C0E0E
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Metastatic behavior of breast cancer subtypes.
@en
type
label
Metastatic behavior of breast cancer subtypes.
@en
prefLabel
Metastatic behavior of breast cancer subtypes.
@en
P2093
P356
P1476
Metastatic behavior of breast cancer subtypes.
@en
P2093
Caroline H Speers
David Voduc
Hagen Kennecke
Karen Gelmon
Rinat Yerushalmi
Ryan Woods
Torsten O Nielsen
P304
P356
10.1200/JCO.2009.25.9820
P407
P577
2010-05-24T00:00:00Z